Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
For the incretin crowd that has the MOA of tirzepatide all figured out here is some new intriguing mouse and primate data from @Amgen with a GIPR antagonist-GLP1R agonist antibody #weightloss #obesity #T2D @CellRepMed cell.com/cell-reports-m For the incretin crowd that has the MOA of tirzepatide all figured out here is some new intriguing mouse and primate data from @Amgen with a GIPR antagonist-GLP1R agonist antibody #weightloss #obesity #T2D @CellRepMed cell.com/cell-reports-m GLP-1 - one incretin to rule them all (therapeutically speaking)
Materials and methods Clinical trial design This was a phase Ib, single centre, open-label study (NCT03350191, ClinicalTrials.gov) with 20 days once daily repeated subcutaneous doses of SAR425899 at 2 different dose regimens (A and B) in overweight to obese T2D patients
4-HDHA eluted at 15.7 min, 14-HDHA at 14.23 min, and 17-HDHA at 18.55 min
These findings suggest that early discontinuation may diminish the cardiovascular benefits of GLP-1 RAs, underscoring the importance of treatment persistence when evaluating real-world outcomes
